M&A highlights from previous weeks…👇
YTD Summary:
Number Announced: 31
Q1 2024 # Announced: 18
Q2 2024 # Announced: 13
HI-Bio
Acquired By: Biogen
Announcement Date: May 22, 2024
Acquisition Price: $1.15B + $650M potential milestone payment
Acquisition Date (Closed): Pending
Lead Asset: Felzartamab
Lead Asset Stage: Phase 2
Indication: Immune-mediated diseases
Proteologix
Acquired By: Johnson & Johnson
Announcement Date: May 16, 2024
Acquisition Price: $850M + potential milestone payment
Acquisition Date (Closed): Pending
Lead Asset: PX128
Lead Asset Stage: Phase 1
Indication: Atopic dermatitis and Asthma
Reneo Pharmaceuticals & OnKure (Merger)
Announcement Date: May 13, 2024
Merger Date (Closed): Pending
Lead Asset: OKI-219
Lead Asset Stage: Phase 1
Lead Asset Indication: Solid tumors
---
Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more
Article History:
RF, DV, DG (05/23/24)
This article is not investment or legal advice.
Comments